Rational Approach to Psychotropic Use in COVID-19 Cases With Psychiatric Comorbidities: Lesson Learnt From a Case Series

Pattnaik, Jigyansa Ipsita; Das, Sudipta Sekhar; Sarkar, Hemlata; Mahasuar, Rajnarayan; Ravan, Jayaprakash Russell

doi:10.1177/02537176211040260

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on available evidence, mood stabilizers are relatively safe in the case of COVID-19. Treatment should be continued in the context of strict monitoring of serum levels, hydration, renal, and liver functions and considering drug interactions, side effects, and the narrow therapeutic range of this psychopharmacological class [ 42 , 48 ].…”

Section: Recommendationsmentioning

confidence: 99%

Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence- and consensus-based recommendations for mental and public health

et al. 2022

View full text Add to dashboard Cite

As COVID-19 becomes endemic, identifying vulnerable population groups for severe infection outcomes and defining rapid and effective preventive and therapeutic strategies remains a public health priority. We performed an umbrella review, including comprehensive studies (meta-analyses and systematic reviews) investigating COVID-19 risk for infection, hospitalization, Intensive Care Unit (ICU) admission, and mortality in people with psychiatric disorders, and outlined evidence-and consensus-based recommendations for overcoming potential barriers that psychiatric patients may experience in preventing and managing COVID-19, and defining optimal therapeutic options and current research priorities in psychiatry. We searched Web of Science, PubMed, and Ovid/PsycINFO databases up to 17 January 2022 for the umbrella review. We synthesized evidence, extracting when available pooled odd ratio estimates for the categories 'any mental disorder' and 'severe mental disorders'. The quality of each study was assessed using the AMSTAR-2 approach and ranking evidence quality. We identified four systematic review/meta-analysis combinations, one metaanalysis, and three systematic reviews, each including up to 28 original studies. Although we rated the quality of studies from moderate to low and the evidence ranged from highly suggestive to nonsignificant, we found consistent evidence that people with mental illness are at increased risk of COVID-19 infection, hospitalization and most importantly mortality, but not of ICU admission. The risk and the burden of COVID-19 in people with mental disorders, in particular those with severe mental illness, can no longer be ignored but demands urgent targeted and persistent action. Twentytwo recommendations are proposed to facilitate this process.

show abstract

Section: Recommendationsmentioning

confidence: 99%